Drug developers face increasingly risky tightrope walk between top-line results and hard data
Even the biggest pharma companies can hype the results of a big drug study, given the curious dance-of-the-seven-veils choreography provided to late-stage data. And the Wall Street Journal is offering up an example to underscore just how perilous this dance can be for all players.
Case in point: Roche and Perjeta. The Swiss pharma giant first offered a top-line glimpse of its positive results for the APHINITY study involving Perjeta, but had to deal with some bitter reactions when analysts got a chance to examine the marginal benefit that has been provided.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.